Europe
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
Roche intends to hold two global meetings with members of the DMD community to provide the stakeholders with as much information as possible.
The good performance we saw in the second quarter has continued and further improved.
The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company.
70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment)
Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs
Independent SMO Panthera Biopartners has opened its first clinical trials site in Preston, Lancashire, UK.
Summit Therapeutics plc announces that management will participate in two panel sessions at the World Antimicrobial Resistance Congress, taking place 7-8 November 2019 in Washington, DC.
A paper discussing recent preclinical advances of Bavarian Nordic’s novel cancer immunotherapy platform was published in the prominent, peer-reviewed, open access journal, Nature Communications.
Presentation at SITC Shows Potential to Flag Solid Tumours as a Target for the Immune System to Attack Using the Company’s DCOne® Cell Vaccine Loaded with a Foreign Antigen
PRESS RELEASES